Abstracts tagged "Sjögren’s syndrome"

Abstract Number: 2233 • ACR Convergence 2025
Spatial Multi-omics Demonstrates Shared Immune States Across Autoimmune Diseases and Target Tissues in the Accelerating Medicines Partnership: Autoimmune and Immune-Mediated Diseases Network (AMP AIM)
Caleb Marlin¹, Roopa Madhu², Erin Theisen³, Liz Bradshaw⁴, Ce Gao⁵, Thomas Eisenhaure⁶, Nicolas Sugiarto⁷, Accelerating Medicines Partnertship: Autoimmune and Immune Mediated Diseases⁸, Jill Buyon⁹, Michelle Petri¹⁰, Brad Rovin¹¹, Victoria Werth¹², Ellen M. Gravallese¹³, Jennifer Anolik¹⁴, Larry Moreland¹⁵, Laura Donlin¹⁶, Christopher Ritchlin¹⁷, Jose Scher¹⁸, Johann Gudjonsson¹⁹, Wilson Liao²⁰, Alexis Ogdie²¹, Caroline Shiboski²², A. Darise Farris¹, Alan Baer²³, Blake M. Warner²⁴, Jose Clemente²⁵, Adriana Heguy²⁶, Michael Brenner²⁷, Nir Hacohen²⁸, Joel Guthridge¹, Judith James¹, Soumya Raychaudhuri²⁹, Lam Tsoi¹⁹, Xiang Zhou³⁰, Joshua Welch³⁰, Rachael Clark³, ilya Korsunsky²⁹, Christopher Lessard¹ and Kevin Wei³¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Brigham and Women's Hospital, Brookline, MA, ³Brigham and Women's Hospital, Boston, ⁴Oklahoma Medical Research Foundation, Oklahoma City, ⁵Division of Rheumatology, Inflammation and Immunity, DOM, BWH; Harvard Medical School, Boston, MA, ⁶Broad Institute, Cambridge, MA, ⁷Broad Institute, Boston, ⁸Multiple Institutions, Oklahoma City, ⁹NYU Grossman School of Medicine, New York, NY, ¹⁰Johns Hopkins University School of Medicine, Timonium, MD, ¹¹The Ohio State University, Columbus, OH, ¹²University of Pennsylvania, Wynnewood, PA, ¹³Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA, ¹⁴University of Rochester Medical Center, Rochester, NY, ¹⁵University of Colorado, Denver, CO, ¹⁶Hospital for Special Surgery, New York, NY, ¹⁷University of Rochester Medical Center, Canandaigua, NY, ¹⁸New York University School of Medicine, New York, NY, ¹⁹University of Michigan, Ann Arbor, MI, ²⁰UCSF, San Francisco, CA, ²¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE, ²²University of California San Francisco, San Francisco, CA, ²³Johns Hopkins University School of Medicine, Baltimore, MD, ²⁴National Institutes of Health, Bethesda, MD, ²⁵Icahn School of Medicine at Mount Sinai, New York, NY, ²⁶NYU Grossman School of Medicine, New York, ²⁷Brigham and Women's Hospital, Harvard Medical School, Newton, MA, ²⁸Broad Institute of MIT Harvard, Cambridge, MA, ²⁹Brigham and Women's Hospital, Boston, MA, ³⁰University of Michigan, Ann Arbor, ³¹Brigham and Women's Hospital at Harvard Medical School, Boston, MA
Background/Purpose: Autoimmune diseases affect more than 23.5 million Americans involving nearly every organ system of the human body. To identify shared, unique, and novel pathways…
Abstract Number: 1667 • ACR Convergence 2025
Recurrent or Incident Pericarditis With Concurrent Autoimmune Disease: Stable Control With Rilonacept Interleukin-1 Pathway Inhibition
Zachary Daniel¹, Summia Afridi¹, Michael Allen² and Khoa Ngo¹, ¹Albany Medical College, Albany, NY, ²Albany Med, Albany, NY
Background/Purpose: Up to 30% of patients with incident pericarditis will develop recurrent pericarditis (RP), with severe impact on quality of life. More than 20% of…
Abstract Number: 1389 • ACR Convergence 2025
Association Of Dry Eye Severity With Salivary Flow In Patients With Primary Sjögren’s Syndrome
Janett C. Riega-Torres¹, Karina Palomo-Arnaud², Jose Martinez-Delgado³, Fernando Morales-Wong³, Jesus Mohamed-Hamsho³, Valeria Mata-Riega², Irma Cantu-Zapata², Luis Medina-Gomez², Miguel Betancourt-De la Torre², Aritze Chong-Amezcua², Dionicio A. Galarza-Delgado⁴ and Karim Mohamed-Noriega³, ¹Rheumatology Service, Hospital Universitario “Dr. Jose Eleuterio Gonzalez”, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico, ²Hospital Universitario "Dr. José Eleuterio González", Rheumatology, Monterrey, Nuevo León, Monterrey, Nuevo Leon, Mexico, ³Hospital Universitario "Dr. José Eleuterio González", Ofthalmology, Monterrey, Nuevo León, Monterrey, Nuevo Leon, Mexico, ⁴Rheumatology Service, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey, Mexico
Background/Purpose: Sjögren’s Syndrome (SS) is a multisystemic autoimmune disease that causes hypofunction of salivary and lacrimal glands, manifesting in xerostomia and xerophthalmia among other systemic…
Abstract Number: 0931 • ACR Convergence 2025
Reduced mitophagy in salivary glands of Sjögren’s disease patients is associated with mitochondrial structural damage
Salvador Campos¹, Sergio Aguilera², Juan Gutiérrez¹, Isabel Castro³, Patricia Carvajal³, Lorena Carvajal¹, Sergio González⁴, Claudio Molina⁵, María-Julieta González⁶ and María-José Barrera⁵, ¹Universidad San Sebastián, Santiago, Region Metropolitana, Chile, ²Clinica Indisa, Santiago, Region Metropolitana, Chile, ³Departamento de Tecnología Médica, Facultad de Medicina, Universidad de Chile, Santiago, Region Metropolitana, Chile, ⁴Escuela de Odontología, Universidad Mayor, Santiago, Region Metropolitana, Chile, ⁵Facultad de Odontología, Universidad San Sebastián, Santiago, Region Metropolitana, Chile, ⁶ICBM, Facultad de Medicina, Universidad de Chile, Santiago, Region Metropolitana, Chile
Background/Purpose: Primary Sjögren's disease (pSjD) is a systemic autoimmune disease characterized mainly by immune-mediated damage to exocrine glands. Previously, we found decreased expression of ATG5…
Abstract Number: 0509 • ACR Convergence 2025
Functional Anti-M3R Autoantibodies in Sjögren’s Disease: From Gland to Circulation
Martha Tsaliki¹, Joshua Cavett², Biji T Kurien³, valerie Lewis³, John Ice⁴, Devavrat Dave⁵, Sina Khosravani⁵, Menerva Racy⁵, Rebecca Wood⁶, Seunghee Cha⁷, A. Darise Farris³, Kristi A. Koelsch⁵ and R. Scofield³, ¹The University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Oklahoma Medicar Research Foundtion, Oklahoma City, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴OKC Veterans Affairs Medical Center, Oklahoma City, OK, ⁵Oklahoma Medical Research Foundation, oklahoma City, ⁶University of Oklahoma Health Sciences Center, Edmond, OK, ⁷University of Florida, Gainesville
Background/Purpose: Sjögren’s disease (SjD) is a systemic autoimmune disease characterized by immune-mediated damage to salivary and lacrimal glands. While autoantibodies against muscarinic type 3 receptor…
Abstract Number: 1247 • ACR Convergence 2024
Pre- and Post-Diagnosis Comparison of the Patient Experience of Sjögren’s Syndrome (SS): A Linguistic Analysis of Global Social Media Conversations
Sarah N. Ali¹, Dorothee Oberdhan¹, Michelle M. Richardson¹, Jordan Amorelli², Amanda Martini² and Jennifer Dandy², ¹Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ, ²Real Chemistry, New York, NY
Background/Purpose: Patients with Sjögren’s Syndrome (SS) often undergo a prolonged and complex path to diagnosis and experience symptom, disease and treatment burdens with multiple co-morbid…
Abstract Number: 1421 • ACR Convergence 2024
Differential Impact of B-cell Targeted Monotherapy and Combination Regimen on the Peripheral Blood Transcriptome of Adults with Active Sjögren Disease
Coziana Ciurtin¹, Lucia Martin-Gutierrez¹, John Casement², Kyle Thompson³, Fai Ng⁴, Andre van Maurik⁵ and Elizabeth Jury¹, ¹University College London, London, United Kingdom, ²Newcastle University, Newcastle, United Kingdom, ³Newcastle University, Newcastle, England, United Kingdom, ⁴Newcastle University, Newcastle upon Tyne, England, United Kingdom, ⁵Precision Medicine, GlaxoSmithKline, Stevenage, United Kingdom
Background/Purpose: Sjögren disease (SD) is characterised by B-cell hyperactivity associated with increased levels of B-lymphocyte stimulator (BlyS), but there are no effective biologic treatments for…
Abstract Number: 1889 • ACR Convergence 2024
Prevalence of Physician-Diagnosed versus Clinically Confirmed Primary Sjögren’s Syndrome (SS) Among Adults in the United States
Cynthia J. Willey¹, Sarah N. Ali² and Rieke Alten³, ¹College of Pharmacy, University of Rhode Island, Kingston, RI, ²Otsuka Pharmaceutical Development and Commercialization, Inc., Princeton, NJ, ³Schlosspark Klinik, University Medicine Berlin, Berlin, Germany
Background/Purpose: Sjögren’s Syndrome (SS) is a systemic autoimmune disorder characterized by inflammation of salivary and lachrymal glands. The clinical spectrum is variable as slow progressive…
Abstract Number: 2299 • ACR Convergence 2024
Clinical and Serological Characteristics of Sjögren’s Disease-related Lymphocytic Interstitial Pneumonia: A Large Multicenter Study
Gaetano La Rocca¹, Francesco Ferro², Marco Sebastiani³, Andreina Manfredi⁴, Caterina Vacchi⁵, Elena Bartoloni Bocci⁶, Martina Nicchi⁷, Fabiola Atzeni⁸, Francesca Cracò⁹, Serena Guiducci¹⁰, Laura Cometi¹¹, Luca Quartuccio¹², Elena Treppo¹², Valeria manfrè¹³, Marta Mosca¹ and Chiara Baldini¹, and Italian Study group on Lung iNvolvement in rheumatic Diseases (ISLaND), ¹University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy, ²Clinical and Experimental Medicine Department, Azienda Ospedaliero-Universitaria Pisana, Pisa, Pisa, Italy, ³Rheumatology Unit, Azienda USL of Piacenza and University of Parma, Parma, Italy, ⁴University of Modena and Reggio Emilia, Modena, ⁵University of Modena and Reggio Emilia, Modena, Italy, ⁶Rheumatology Unit. Department of Medicine, Perugia, Perugia, Italy, ⁷Rheumatology Unit, Department of Medicine, University of Perugia, Perugia, ⁸University of Messina, Italy, Messina, Italy, ⁹University of Messina, Messina, Italy, ¹⁰University of Florence, Pistoia, Italy, ¹¹University of Florence, Florence, Italy, ¹²Division of Rheumatology, Department of Medicine (DMED), University of Udine, Udine, Italy, Udine, Italy, ¹³University of Udine, Udine
Background/Purpose: Interstitial Lung Disease (ILD) in patients with Primary Sjögren’s Disease (SjD) is very heterogeneous in terms of pathophysiologic mechanisms, clinical course, radiologic and histologic…
Abstract Number: 2629 • ACR Convergence 2024
Deciphering Salivary Gland Inflammation in Sjögren’s Syndrome Reveals Shared and Autoantibody-Specific Immune Cell Heterogeneity
Jun Inamo¹, Masaru Takeshita², Katsuya Suzuki², Kazuyuki Tsunoda², Satoshi Usuda², Junko Kuramoto², Tsutomu Takeuchi³ and Yuko Kaneko⁴, ¹University of Colorado School of Medicine, Aurora, CO, ²Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ³Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, JP, Shinjuku-ku, Tokyo, Japan
Background/Purpose: Sjögren's syndrome (SS) is an autoimmune disease characterized by progressive immune cell-mediated destruction of the exocrine glands. SS patients have distinct clinical phenotypes based…
Abstract Number: 1250 • ACR Convergence 2024
Qualitative Study on Patient-Reported Outcome Measures in Patients with Sjögren’s Disease
Suzanne Arends¹, Jiyoon C. Choi², Brandon Becker², Teresa Edwards³, Antoine Sreih⁴, Antonia Christodoulou⁴ and Vibeke Strand⁵, ¹Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²Bristol Myers Squibb, Princeton, ³RTI International, Research Triangle Park, NC, ⁴Bristol Myers Squibb, Princeton, NJ, ⁵Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: Sjögren’s disease (SjD) is a chronic, systemic autoimmune disease characterized by lymphocytic infiltration of the endocrine glands. Globally, SjD affects between 0.01% and 0.05%…
Abstract Number: 1422 • ACR Convergence 2024
Evaluation of Salivary Gland Focus Score in Sjogren’s Disease Using Deep Learning: A Step Towards Tissue Biomarker Discovery
Konstantinos Panagiotopoulos¹, Nikos Tsiknakis², Dimitrios Zaridis³, Athanasios Tzioufas⁴, Dimitrios I. Fotiadis⁵ and Andreas Goules⁶, ¹Pathophysiology Department, National and Kapodistrian University of Athens, Athens, Greece, ²Karolinska Institutet, Department of Oncology-Pathology, Computational BioMedicine Laboratory, Foundation for Research and Technology Hellas, Stockholm, Sweden, ³School of Electrical & Computer Engineering and Biomedical Research Institute National Technical University of Athens and FORTH, Unit of Medical Technology and Intelligent Information Systems, Department of Materials Science and Engineering, University of Ioannina, Ioannina, Ioannina, Greece, ⁴LAIKO HOSPITAL, Athens, Greece, ⁵Unit of Medical Technology and Intelligent Information Systems, University of Ioannina & FORTH, Ioannina, Greece, ⁶GENERAL HOSPITAL LAIKO ATHENS, Athens, Greece
Background/Purpose: Sjogren's Disease (SjD) is characterized by focal sieladenitis in minor salivary gland biopsies (mSGB), which is evaluated using the Focus Score (FS). FS ≥…
Abstract Number: 1909 • ACR Convergence 2024
Racial Disparities in Ocular Complications of Systemic Rheumatic Diseases: A Retrospective Cross-Sectional Study
Insa Mannstadt¹, Yiyuan Wu² and Bella Mehta³, ¹Columbia University VP&S, New York, NY, ²Weill Cornell Medicine, New York, NY, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: While systemic rheumatic diseases, including Sjogren's syndrome, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and spondyloarthropathies, are known to have severe ophthalmologic manifestations, there…
Abstract Number: 2300 • ACR Convergence 2024
Activation of Tissue-Resident T Cells in Sjögren’s Disease with Human Salivary Organoids
Brandon Law¹, Rahmatullah Rahmati² and Andrew Luster³, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts Eye & Ear, Boston, MA, ³Massachusetts General Hospital, Charlestown, MA
Background/Purpose: Sjögren's disease (SjD) is a chronic autoimmune disease characterized by lymphocytic infiltration of exocrine glands, particularly the salivary glands. These focal lymphocytic infiltrates are…
Abstract Number: 2630 • ACR Convergence 2024
Identification of Molecular Biomarkers for Sjögren’s Disease Stratification via a Deep Learning Foundation Model Dedicated to Immune-Mediated and Inflammatory Disease
Aygalic Jara-Mikolajczak¹, Zachary Abessera¹, Martin Rethoret-Pasty¹, Elisa Mazuir¹, Apolline Bruley¹, Wan Fai Ng², Marta Alarcon-Riquelme³, Michele Bombardieri⁴, Simon Bowman⁵, Elena Pontarini⁶, Jacques-Eric Gottenberg⁷, Xavier Mariette⁸, Laurence LAIGLE⁹, Julien Duquesne¹, Philippe Moigeon¹⁰ and Vincent Bouget¹¹, and NECESSITY Consortium, ¹Scienta Lab, Paris, France, ²Department of Rheumatology, Newcastle University, & HRB Clinical Research Facility, University College Cork, Newcastle upon Tyne, United Kingdom, ³Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ⁴Centre for Experimental Medicine and Rheumatology, The William Harvey Research Institute, Queen Mary University of London, London, United Kingdom, ⁵Department of Rheumatology, University Hospital Birmingham, Birmingham, United Kingdom, ⁶William Harvey Research Institute, London, United Kingdom, ⁷Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, ⁸Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France, ⁹Servier Laboratories, France, SURESNES, France, ¹⁰Servier Laboratories, France, Gif sur Yvette, France, ¹¹Scienta Lab, Gif-sur-Yvette, France
Background/Purpose: Sjögren’s Disease (SjD) exhibits heterogeneity in clinical manifestations and underlying biology. This heterogeneity complicates drug development, with no targeted therapy approved to date. Identifying…

« Previous Page
1
…
5
6
7
8
9
…
24
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].